Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years

EARLY_PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

September 13, 2023

Study Completion Date

September 13, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine

one booster dose intramuscularly in the deltoid muscle of the upper arm.

Trial Locations (1)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou